Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for crohn's fistula

Stem Cells

Volumn 31, Issue 11, 2013, Pages 2575-2581

  Lee, Woo Yong ^a   Park, Kyu Joo ^b   Cho, Yong Beom ^a   Yoon, Sang Nam ^c   Song, Kee Ho ^d   Kim, Do Sun ^d   Jung, Sang Hun ^e   Kim, Mihyung ^f   Yoo, Hee Won ^f   Kim, Inok ^f,g   Ha, Hunjoo ^g   Yu, Chang Sik ^c  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Daehang Hospital   (South Korea)

^e Yeungnam University Hospital   (South Korea)

^f Anterogen Co Ltd   (South Korea)

^g Center for Cell Signaling and Drug Discovery Research   (South Korea)

Author keywords

Adipose tissue derived stem cells; Autologous stem cells; Complete closure of fistula; Crohn's fistula; Sustained response

Indexed keywords

FIBRIN GLUE;

ADIPOSE TISSUE; ADIPOSE TISSUE DERIVED STEM CELL; ADULT; ANAL BLEEDING; ANAL PAIN; ARTICLE; BLEEDING; CLINICAL ARTICLE; CROHN DISEASE; CROHN FISTULAE; FEMALE; FISTULA; FOLLOW UP; HUMAN; INFLAMMATION; MALE; OBSERVATIONAL STUDY; PAIN; PATIENT SAFETY; PERITONITIS; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE PAIN; RECURRENT DISEASE; STEM CELL; THERAPY EFFECT; TREATMENT OUTCOME;

FISTULA;

ADIPOSE TISSUE-DERIVED STEM CELLS; AUTOLOGOUS STEM CELLS; COMPLETE CLOSURE OF FISTULA; CROHN'S FISTULA; SUSTAINED RESPONSE;

ADIPOSE TISSUE; ADULT; CELL GROWTH PROCESSES; CROHN DISEASE; FEMALE; FISTULA; HUMANS; MALE; RECTAL FISTULA; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84887040879     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1357     Document Type: Article

References (43)

1. Economou M, Pappas G. New global map of Crohn's disease: Genetic, environmental, and socioeconomic correlations. Inflamm Bowel Dis 2008; 14: 709-720. (Pubitemid 351742998)
2. Yang SK, Yun S, Kim JH et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: A KASID study. Inflamm Bowel Dis 2008; 14: 542-549. (Pubitemid 351571835)
3. Sands BE. From symptom to diagnosis: Clinical distinctions among various forms of intestinal inflammation. Gastroenterology 2004; 126: 1518-1532. (Pubitemid 38649870)
4. American Gastroenterological Association Clinical Practice Committee. American Gastroenterological Association medical position statement: Perianal Crohn's disease. Gastroenterology 2003; 125: 1503-1507.
5. Farmer RG, Hawk WA, Turnbull RB Jr. et al. Clinical patterns in Crohn's disease: A statistical study of 615 cases. Gastroenterology 1975; 68(4 pt 1): 627-635.
6. Greenstein AJ, Kark AE, Dreiling DA. Crohn's disease of the colon. I. Fistula in Crohn's disease of the colon, classification presenting features and management in 63 patients. Am J Gastroenterol 1974; 62: 419-429.
7. Levy C, Tremaine WJ. Management of Internal Fistulas in Crohn's disease. Inflamm Bowel Dis 2002; 8: 106-111. (Pubitemid 34213509)
8. Williams JG, MacLeod CA, Rothenberger DA et al. Seton treatment of high anal fistulae. Br J Surg 1991; 78: 1159-1161.
9. van Koperen P.J., Safiruddin F, Bemelman WA et al. Outcome of surgical treatment for fistula in ano in Crohn's disease. Br J Surg 2009; 96: 675-679.
10. Ritchie RD, Sackier JM, Hodde JP. Incontinence rates after cutting seton treatment for anal fistula. Colorectal Dis 2009; 11: 564-571.
11. Sciaudone G, Di Stazio C, Limongelli P et al. Treatment of complex perianal fistulas in Crohn disease: Infliximab, surgery or combined approach. Can J Surg 2010; 53: 299-304.
12. Tozer PJ, Burling D, Gupta A et al. Review article: Medical, surgical and radiological management of perianal Crohn's fistulas. Aliment Pharmacol Ther 2011; 33: 5-22.
13. Van Assche G., Vanbeckevoort D, Bielen D et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol 2003; 98: 332-339. (Pubitemid 36232382)
14. Taxonera C, Schwartz DA, García-Olmo D. Emerging treatments for complex perianal fistula in Crohn's disease. World J Gastroenterol 2009; 15: 4263-4272.
15. Whiteford MH, Kilkenny J 3rd, Hyman N et al. Practice parameters for the treatment of perianal abscess and fistula-in-ano (revised). Dis Colon Rectum 2005; 48: 1337-1342. (Pubitemid 40933859)
16. Cassinotti A, Annaloro C, Ardizzone S et al. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease. Gut 2008; 57: 211-217. (Pubitemid 351158049)
17. Ciccocioppo R, Bernardo ME, Sgarella A et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 2011; 60: 788-798.
18. Singh UP, Singh NP, Singh B et al. Stem cells as potential therapeutic targets for inflammatory bowel Disease. Front Biosci(Schol Ed) 2010; 2: 993-1008.
19. García-Olmo D., García-Arranz M, García LG et al. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn's disease: A new cell-based therapy. Int J Colorectal Dis 2003; 18: 451-454.
20. García-Olmo D., García-Arranz M, Herreros D et al. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 2005; 48: 1416-1423. (Pubitemid 40933870)
21. Garcia-Olmo D., Herreros D, De-La-Quintana P et al. Adipose-derived stem cells in Crohn's rectovaginal fistula. Case Report Med 2010; 2010: 961758.
22. Garcia-Olmo D., Herreros D, Pascual M et al. Treatment of enterocuta-neous fistula in Crohn's Disease with adipose-derived stem cells: A comparison of protocols with and without cell expansion. Int J Colo-rectal Dis 2009; 24: 27-30.
23. Garcia-Olmo D., Herreros D, Pascual I et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: A phase II clinical trial. Dis Colon Rectum 2009; 52: 79-86.
24. Cho YB, Lee WY, Park KJ et al. Autologous adipose tissue-derived stem cells for the treatment of Crohn's fistula: A phase I clinical study. Cell Transplant 2013; 22: 279-285.
25. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-1405. (Pubitemid 29205403)
26. Kim M, Kim I, Lee SK et al. Clinical trial of autologous differentiated adipocytes from stem cells derived from human adipose tissue. Der-matol Surg 2011; 37: 750-759.
27. Christman KL, Vardanian AJ, Fang Q et al. Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium. J Am Coll Cardiol 2004; 44: 654-660. (Pubitemid 39089073)
28. Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-885. (Pubitemid 38252535)
29. Guadalajara H, Herreros D, De-La-Quintana P et al. Long-term follow-up of patients undergoing adipose-derived adult stem cell administration to treat complex perianal fistulas. Int J Colorectal Dis 2012; 27: 595-600.
30. Le Blanc K. Mesenchymal stromal cells: Tissue repair and immune modulation. Cytotherapy 2006; 8: 559-561. (Pubitemid 44869856)
31. Yagi H, Soto-Gutierrez A, Parekkadan B et al. Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant 2010; 19: 667-679.
32. Yoo KH, Jang IK, Lee MW et al. Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. Cell Immunol 2009; 259: 150-156.
33. Di Nicola M., Carlo-Stella C, Magni M et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838-3843. (Pubitemid 34534559)
34. Krampera M, Glennie S, Dyson J et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101: 3722-3729. (Pubitemid 36857965)
35. Ren G, Zhang L, Zhao X et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141-150. (Pubitemid 351181031)
36. Prigione I, Benvenuto F, Bocca P et al. Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. Stem Cells 2009; 27: 693-702.
37. Corcione A, Benvenuto F, Ferretti E et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107: 367-372. (Pubitemid 43053565)
38. Raffaghello L, Bianchi G, Bertolotto M et al. Human mesenchymal stem cells inhibit neutrophil apoptosis: A model for neutrophil preservation in the bone marrow niche. Stem Cells 2008; 26: 151-162.
39. Groh ME, Maitra B, Szekely E et al. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol 2005; 33: 928-934. (Pubitemid 40982660)
40. Batten P, Sarathchandra P, Antoniw JW et al. Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: Relevance to tissue engineering human heart valves. Tissue Eng 2006; 12: 2263-2273. (Pubitemid 44734984)
41. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-1822. (Pubitemid 40223708)
42. Sato K, Ozaki K, Oh I et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007; 109: 228-234. (Pubitemid 46053063)
43. Meisel R, Zibert A, Laryea M et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxyge-nase-mediated tryptophan degradation. Blood 2004; 103: 4619-4621. (Pubitemid 38745993)